Leimgruber A, Jaques W A, Spaeth P J
Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Int Arch Allergy Immunol. 1993;101(1):107-12. doi: 10.1159/000236506.
We report on the successful use of a pasteurized C1 inhibitor (C1-INH) concentrate during dental surgery of a patient affected by hereditary angioedema. The patient recovered fully without complications or side effects. Within 30 min, the first 1,000 U of C1-INH concentrate raised C1-INH concentration from 19 to 55% and function from 40 to 90% of the normal mean. When measured 4 h after the second injection, a further increase of the C1-INH concentration to 86% and a function of 106% relative to the normal mean was observed. Within 2 weeks C1-INH concentration returned to pretreatment level, while the function remained above this value. Serum liver enzyme values did not change and no anti-C1-INH alloantibodies were detected 10 months post-replacement therapy. We conclude that in patients affected by C1-INH deficiency, dental surgery and likely other traumatic procedures can be safely performed in conjunction with C1-INH replacement therapy even without preliminary treatment.
我们报告了在一名患有遗传性血管性水肿患者的牙科手术中成功使用经巴氏消毒的C1抑制剂（C1-INH）浓缩物的情况。患者完全康复，未出现并发症或副作用。在30分钟内，首次注射的1000 U C1-INH浓缩物使C1-INH浓度从19%提高到55%，功能从正常平均值的40%提高到90%。在第二次注射后4小时测量时，观察到C1-INH浓度进一步升高至86%，相对于正常平均值的功能为106%。在2周内，C1-INH浓度恢复到治疗前水平，而功能仍高于该值。血清肝酶值未发生变化，在替代治疗后10个月未检测到抗C1-INH同种抗体。我们得出结论，对于受C1-INH缺乏影响的患者，即使不进行初步治疗，牙科手术以及可能的其他创伤性手术也可与C1-INH替代治疗联合安全进行。
